COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,033 Articles (22,627 medRxiv, 8,406 bioRxiv)

Most recent first Previous |  Page 2884: Articles 28831-28840  | Next

Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance
Freeman, B., Lester, S., Mills, L., Rasheed, M. A. U., Moye, S., Abiona, O., Hutchinson, G., Morales-Betoulle, M., Krapinunaya, I., Gibbons, A., Chiang, C.-F., Cannon, D., Klena, J., Johnson, J. A., Owen, S. M., Graham, B. S., Corbett, K. S., Thornburg, N. J.
10.1101/2020.04.24.057323 — Posted: 2020-04-24
Evolution and molecular characteristics of SARS-CoV-2 genome
Bai, Y., Jiang, D., Lon, J. R., Chen, X., Hu, M., Lin, S., Chen, Z., Meng, Y., Du, H.
10.1101/2020.04.24.058933 — Posted: 2020-04-24 Discussion: Onsite
Genomic, geographic and temporal distributions of SARS-CoV-2 mutations
Yang, H.-C., Chen, C.-h., Wang, J.-H., Liao, H.-C., Yang, C.-T., Chen, C.-W., Lin, Y.-C., Kao, C.-H., Liao, J. C.
10.1101/2020.04.22.055863 — Posted: 2020-04-24
Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells
Stanifer, M. L., Kee, C., Cortese, M., triana, S., Mukenhirn, M., Kraeusslich, H.-G., Alexandrov, T., Bartenschlager, R., Boulant, S.
10.1101/2020.04.24.059667 — Posted: 2020-04-24 Discussion: Offsite
Introductions and early spread of SARS-CoV-2 in France
Gambaro, F., Baidaliuk, A., Behillil, S., Donati, F., Albert, M., Alexandru, A., Vanpeene, M., Bizard, M., Brisebarre, A., Barbet, M., Derrar, F., van der Werf, S., Enouf, V., Simon-Loriere, E.
10.1101/2020.04.24.059576 — Posted: 2020-04-24 Discussion: Offsite
Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a
Blanchard, E. L., Vanover, D., Bawage, S. S., Tiwari, P. M., Rotolo, L., Beyersdorf, J., Peck, H. E., Bruno, N. C., Hincapie, R., Finn, M. G., Michel, F., Lafontaine, E. R., Hogan, R. J., Zurla, C., Santangelo, P. J.
10.1101/2020.04.24.060418 — Posted: 2020-04-24 Discussion: Offsite
Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia
Rodon, J., Noguera-Julian, M., Erkizia, I., Valencia, A., Guallar, V., Carrillo, J., Blanco, J., Segales, J., Clotet, B., Vergara-Alert, J., Izquierdo-Useros, N.
10.1101/2020.04.23.055756 — Posted: 2020-04-24
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
Musarrat, F., Chouljenko, V., Nabi, R., Dahai, A., Jois, S., Kousoulas, K.
10.1101/2020.04.24.060376 — Posted: 2020-04-24 Discussion: Offsite
Comparison of commercial RT-PCR diagnostic kits for COVID-19
van Kasteren, P. B., van der Veer, B., Brink, S. v. d., Wijsman, L., de Jonge, J., van den Brandt, A.-M., Molenkamp, R., Reusken, C. B. E. M., Meijer, A.
10.1101/2020.04.22.056747 — Posted: 2020-04-24
Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations.
Russo, R., Andolfo, I., Lasorsa, V. A., Iolascon, A., Capasso, M.
10.1101/2020.04.23.057190 — Posted: 2020-04-24 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).